CRISPR Therapeutics shares saw a significant drop on Thursday morning after an announcement that the FDA placed a clinical hold on the Investigational New Drug Application (IND) for CTX001 for the treatment…
Chris Lange While these four stocks are better suited for accounts that have a higher risk tolerance, they all make good sense now and all have outstanding upside potential.
Lee Jackson Merrill Lynch has taken a look at the biotech industry and made a few picks that could play out in 2018.
The top analyst upgrades, downgrades and other research calls from Friday include Albermarle, Allergan, Boston Scientific, eBay, FedEx, Gogo, LendingTree, Nokia, UPS and Vertex Pharmaceuticals.
24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February.
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming…
Jefferies has put together a list of 10 biotech companies that could have developments coming up in the next two weeks to start the year.
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
While these eight stocks are not being touted as Credit Suisse's formal top picks for 2018, the timeline sure sets them up to be among the top contenders.
The top analyst upgrades, downgrades and other research calls include American Airlines, Boeing, Cabot Oil & Gas, Pandora Media, Southern Co. and Vertex Pharmaceuticals.
Wednesday was a relatively positive day for the U.S. broad markets with green arrows across the board with a few exceptions. Crude oil was up again, but this time Oil & Gas…
Shares of Vertex Pharmaceuticals shot up after the company announced dramatic results from its early and mid-stage trials in cystic fibrosis. The stock pushed to an all-time high on the back of…
Chris Lange Stocks were indicated to open only slightly higher on Wednesday after a mixed bag of corporate earnings. What investors need to understand is that the major equity indexes remain just under all-time…
The top analyst upgrades, downgrades and other research calls from Tuesday include Agilent, Apple, Citigroup, Exxon, M&T Bank, Snap, Toyota and Twitter.
Many on Wall Street feel that some of the more speculative institutional tech money may be rotating into the biotechs, and with good reason.
